Annonce • Jul 16
Alamar Biosciences, Inc. Announces Board and Committee Changes Alamar Biosciences, Inc. was deeply saddened to report that Ian Ratcliffe, a member of the Company's board of directors, passed away on July 5, 2026. Ian Ratcliffe served as an independent director on the Board since February 2024. Following Ian Ratcliffe's passing, the Board decreased the number of authorized directors constituting the full Board to five and appointed Nicholas Naclerio, Ph.D., to the Audit Committee of the Board. Annonce • Jul 15
Alamar Biosciences, Inc. to Report Q2, 2026 Results on Aug 10, 2026 Alamar Biosciences, Inc. announced that they will report Q2, 2026 results After-Market on Aug 10, 2026 Actualités en direct • Jul 14
Alamar Biosciences Joins Major University Effort on Nationwide Neurodegenerative Biomarker Study Alamar Biosciences is partnering with leading research universities on a national proteomics initiative that will use its NULISAseq Neuro 220 panel to profile about 21,000 plasma samples from 10,000 participants for blood-based biomarkers linked to Alzheimer’s and other neurodegenerative diseases.
The project will create a large, publicly accessible dataset tied to National Alzheimer’s Coordinating Center IDs and is part of Alamar’s CLARiTI portfolio, with plans for a national AI-focused data challenge to support discovery.
Alamar Biosciences shares trade at US$27.40, with the stock up 24.5% over the past 30 days.
Having its Neuro 220 panel embedded in a national, open-data effort could help Alamar Biosciences build credibility in neurobiology tools and AI-driven biomarker discovery, while also exposing the platform to a broad base of academic and clinical users. Annonce • Jul 13
Alamar Biosciences Partners With Research Universities To Launch National Proteomics Initiative Using NULISAseq Neuro 220 Panel Alamar Biosciences partnered with research universities to launch a national-scale proteomics initiative using Alamar Biosciences’ NULISAseq Neuro 220 panel to accelerate biomarker discovery and validation for Alzheimer’s disease and related neurodegenerative conditions. The project is co-led by professors Sarah Biber, PhD, at Washington University in St. Louis; Sterling Johnson, PhD, at the University of Wisconsin; and Tatiana Foroud, PhD, director of the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) at Indiana University. The project will generate large-scale plasma proteomic data from approximately 21,000 samples collected from 10,000 Alzheimer’s Disease Research Center (ADRC) participants across the United States. Samples are stored at NCRAD, providing a centralized national infrastructure for coordinated access and biomarker generation at scale. Profiling will use Alamar Biosciences’ NULISAseq Neuro 220 panel, enhanced with a newly added eMTBR-Tau assay that enables simultaneous blood-based representation of tau tangle burden alongside a broad panel of neurodegeneration and neuroinflammation biomarkers. The panel also offers the largest number of brain-derived Tau targets along with assays relevant to alpha-synuclein biology and other protein aggregation markers, creating a unique opportunity to study multiple neurodegenerative disease pathways in the same deeply characterized participants. The project is part of the CLARiTI portfolio and leverages its infrastructure to support coordinated sample access and harmonized data workflows. The effort has been advanced through sustained partnerships with the Alzheimer’s Association, the Robertson Foundation, an anonymous foundation, and important implementation and data-sharing support from the Alzheimer’s Disease Data Initiative. All data generated through the initiative will be made freely available to the global research community. A central goal is the creation of an open, publicly accessible proteomic dataset linked to National Alzheimer’s Coordinating Center (NACC) IDs. This linkage will allow researchers to connect the new proteomic profiles with rich longitudinal data available through the ADRC Program, including clinical, cognitive, neuroimaging, genetic, genomic, fluid biomarker, and neuropathology data. AI and computational teams will apply multimodal approaches for disease classification, biomarker discovery, and prediction of neurodegenerative disease progression. The next phase of the project will include a national data challenge inviting the broader research community to develop and test new analytical methods using this resource. Actualités en direct • Jul 08
Alamar Biosciences Unveils First Multiplexed Immunoassay Targeting Alzheimer’s eMTBR-Tau Biomarker Alamar Biosciences has launched the first commercial multiplexed blood-based immunoassay for the Alzheimer’s biomarker eMTBR-Tau, available within its NULISAseq Neuro 220 panel kits and as a single-plex test through its Technology Access Program, with new clinical data slated for presentation at AAIC 2026.
The eMTBR-Tau assay targets a plasma biomarker tied to tau tangle pathology and Alzheimer’s progression, expanding Alamar Biosciences’ neuro-focused offering and providing researchers with a more precise tool to measure disease-related tau biology.
Alamar Biosciences’ stock trades at $25.23, with the share price up 22.8% over the past 30 days.
This launch puts more attention on Alamar Biosciences’ role in Alzheimer’s research tools, and investor outcomes will depend on how widely researchers and partners adopt the eMTBR-Tau assay and whether it leads to durable assay demand. Annonce • Jul 08
Alamar Biosciences Launches the First Multiplexed Blood-Based Immunoassay for eMTBR-Tau Alamar Biosciences, Inc. launched the first commercial eMTBR-Tau immunoassay, now available in the NULISAseq Neuro 220 multiplexed panel kits, deployable on the entire installed base of ARGO HT instruments, and as a single-plex assay through the company’s Technology Access Program. The assay measures eMTBR-Tau, a plasma biomarker that specifically reflects tau tangle pathology and has demonstrated strong associations with cognitive decline, clinical disease staging, and therapeutic response monitoring for Alzheimer’s disease. Immunoassay for eMTBR-Tau is available in the NULISAseq Neuro 220 panel and as a single-plex assay through the Technology Access Program. eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease. A definitive diagnosis of Alzheimer’s disease requires evidence of two hallmark pathologies: amyloid plaques and tau neurofibrillary tangles. Until recently, only one of these could be measured in blood: pTau-217, which serves as an indicator of amyloid pathology. However, a positive pTau-217 result alone is insufficient for a confirmatory diagnosis, as many individuals with amyloid accumulation have not yet developed tau tangles. Historically, measuring tau tangle burden required tau PET imaging, a method that is accurate but expensive and operationally complex. Recent studies have shown that a blood-based eMTBR-tau243 assay, based on mass spectrometry, correlates strongly with tau tangle burden, making it a promising blood-based surrogate for tau PET imaging. Alamar’s NULISA platform delivers a broadly accessible eMTBR-Tau assay that specifically targets the MTBR fragment that is generated by endogenous cleavage at site 256. The highly scalable assay measures eMTBR-Tau at attomolar sensitivity, multiplexed with other key neurodegeneration and neuroinflammation biomarkers from a single low volume sample. Beyond diagnosis, the close association between eMTBR-Tau levels and tau tangle burden may allow researchers to directly measure biological response to tau-targeted therapies and address a critical unmet need for a blood-based biomarker of treatment efficacy. Alamar will showcase eMTBR-Tau data at its workshop at the Alzheimer’s Association International Conference 2026 in London on Tuesday, July 14, where researchers will present performance results and clinical findings from studies using the NULISA platform. The workshop will include presentations covering the assay’s analytical performance, correlation with tau PET imaging, and the ability to stratify patients across Alzheimer’s disease stages. The NULISAseq Neuro 220 Panel with eMTBR-Tau is available now. Actualités en direct • Jun 04
Alamar Biosciences Launches Home Fingerstick Kit for Ultra Sensitive Multiplex Proteomics Assays Alamar Biosciences launched the NULISA Dried Blood Spot (DBS) Extraction Kit, allowing its ultra high-sensitivity, multiplex proteomics assays to run on small fingerstick blood samples collected at home.
The kit is designed to support longitudinal and decentralized translational studies in neurology, inflammation and population health.
The company positions this DBS capability as a way to make proteomics more accessible for population-based screening programs and remote sample collection.
This move pushes Alamar’s platform further into remote and decentralized research workflows, which can matter for adoption by academic centers, contract research groups and potential biopharma partners.
Investors may want to watch how quickly the DBS kit is incorporated into real-world studies, since usage levels and reference customers could become key indicators of commercial traction for Alamar’s technology. Annonce • Jun 03
Alamar Biosciences Launches Nulisa Dried Blood Spot Extraction Kit Alamar Biosciences, Inc. launched the NULISA Dried Blood Spot (DBS) Extraction Kit, enabling researchers to run NULISA assays on microsamples collected at home, unlocking longitudinal and decentralized translational study designs in neurology, inflammation, and population health that cannot be supported by venous blood draws alone. NULISA DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices. Dried blood spot sampling turns a few drops of blood into a dried, ambient-shippable specimen. For proteomics, it has been challenging for researchers to recover protein signals from extremely small sample volumes, across different collection devices, without losing the low-abundance biology they are trying to measure. The NULISA DBS Extraction Kit addresses these challenges with a standardized workflow for multiplex protein measurement from blood samples, collected on remote sampling devices and shipped at ambient temperature. The workflow connects remote sample collection to Alamar’s NULISA technology, enabling ultra-sensitive detection of low-abundance protein biomarkers in non-invasive biofluids. The NULISA platform offers ultra-high sensitivity, high specificity, flexible multiplexing, a broad dynamic range, and automated workflows. In validation studies, Alamar demonstrated 85–95% target detectability across its NULISA CNS and Inflammation panels on most supported microsampling platforms. The combination of the ARGO HT instrument design and the simplified collection and transport of dried blood spot microsamples unlocks proteomics in settings where it hasn't been practical, such as specialty clinics, regional labs, and point-of-care environments. The NULISA DBS Extraction Kit standardizes protein extraction across dried blood spot and dried plasma spot microsamples collected on leading third-party microsampling devices, including Capitainer, Telimmune, Mitra, and Tasso. The NULISA DBS Extraction Kit is now available. New Risk • May 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$67m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$67m free cash flow). Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$32m net loss in 3 years). Reported Earnings • May 14
First quarter 2026 earnings released First quarter 2026 results: US$1.74 loss per share. Net loss: US$21.3m (flat on 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US. Annonce • May 01
Alamar Biosciences, Inc. to Report Q1, 2026 Results on May 08, 2026 Alamar Biosciences, Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026 Annonce • Apr 18
Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million. Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 11,250,000
Price\Range: $17
Discount Per Security: $1.19
Transaction Features: Sponsor Backed Offering